Andrew Joseph Muir

Andrew Joseph Muir

Auto-generated profile, based on publicly available information

Andrew Joseph Muir

Division of Gastroenterology, Department of Medicine, Duke University School of Medicine

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
AMAndrew J. Muir
Andrew J. Muir
CLCynthia Levy
Cynthia Levy
HJHarry L.A. Janssen
Harry L.A. Janssen
AMAldo J. Montano‐Loza
Aldo J. Montano‐Loza
MSMitchell L. Shiffman
Mitchell L. Shiffman
TIThe GS‐US‐321‐0102 Investigators
The GS‐US‐321‐0102 Investigators

7 February 2022 in Hepatology
Verified
Journal Article
Open access
PDF file
ASArun Sanyal
Arun Sanyal
QAQuentin M. Anstee
Quentin M. Anstee
MTMichael Trauner
Michael Trauner
ELEric J. Lawitz
Eric J. Lawitz
MAManal F. Abdelmalek
Manal F. Abdelmalek
RMRobert P. Myers
Robert P. Myers
Background and Aims: Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver‐related complications in patients with NASH cirrhosis. Approach and Results: Patients with compensated cirrhosis due to NASH were enrolled in two placebo‐controlled trials of simtuzumab and selonsertib. Liver fibrosis at baseline and week 48 (W48) was staged by NASH Clinical Research Network (CRN) and Ishak classifications and a machine learning (ML) approach, hepatic collagen and alpha‐smooth muscle actin (α‐SMA) expression were quantified by morphometry, liver stiffness (LS) was measured by transient elastography, and serum NITs (enhanced liver fibrosis [ELF], NAFLD fibrosis score [NFS], and Fibrosis‐4 index [FIB‐4]) were calculated. Cox regression determined associations between these parameters at baseline and their changes over time with adjudicated liver‐related clinical events. Among 1,135 patients, 709 (62%) had Ishak stage 6 fibrosis, and median ELF and LS were 10.66 and 21.1 kPa, respectively. During a median follow‐up of 16.6 months, 71 (6.3%) had a liver‐related event; associated baseline factors included Ishak stage 6 fibrosis, and higher hepatic collagen, α‐SMA expression, ML‐based fibrosis parameters, LS, ELF, NFS, and FIB‐4. Cirrhosis regression observed in 16% (176/1,135) between BL and W48 was associated with a lower risk of events versus nonregression (1.1% [2/176] vs. 7.2% [69/957]; HR, 0.16; 95% CI, 0.04, 0.65 [p = 0.0104]). Conversely, after adjustment for baseline values, increases in hepatic collagen, α‐SMA, ML‐based fibrosis parameters, NFS, and LS were associated with an increased risk of events. Conclusions: In patients with compensated cirrhosis due to NASH, regression of fibrosis is associated with a reduction in liver‐related complications. These data support the utility of histologic fibrosis regression and NITs as clinical trial endpoints for NASH cirrhosis.

5 May 2015 in JAMA
Verified
Journal Article
Open access
PDF file
AMAndrew J. Muir
Andrew J. Muir
FPFred Poordad
Fred Poordad
JLJacob Lalezari
Jacob Lalezari
GEGregory Everson
Gregory Everson
GDGregory J. Dore
Gregory J. Dore
PYPhilip D. Yin
Philip D. Yin
Chronic hepatitis C virus (HCV) infection remains a substantial cause of chronic liver disease, affecting approximately 130 to 150 million individuals worldwide.1 An estimated 20% of patients with chronic HCV infection will develop cirrhosis.2 The prevalence of cirrhosis is increasing, primarily from continuing disease progression in an aging population that acquired HCV infection prior to widespread HCV testing and blood screening.3 Patients with cirrhosis have increased risk of severe sequelae, such as hepatic decompensation, hepatocellular carcinoma, and death.2 Conversely, clearance of HCV infection with effective treatment reduces the risk of disease progression and the need for liver transplantation, and can lead to cirrhosis regression and improved survival.4-6

28 January 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KWKara Wegermann
Kara Wegermann
JWJulius M. Wilder
Julius M. Wilder
APAlice Parish
Alice Parish
DNDonna Niedzwiecki
Donna Niedzwiecki
ZGZiad F. Gellad
Ziad F. Gellad
YPYuval A. Patel
Yuval A. Patel

1 May 2014 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AMAndrew J Muir
Andrew J Muir
Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi). The interferon-free regimen of sofosbuvir and ribavirin is now available for genotype 2 and 3 patients. This regimen for 12 weeks is highly effective for genotype 2, whereas genotype 3 has proven to be more challenging and requires 24 weeks of therapy. Genotype 1 patients have reduced exposure to peginterferon-α with a 12-week regimen with sofosbuvir and a 24-week regimen with simeprevir. Genotype 4, 5, and 6 patients also respond well to the regimen of sofosbuvir, peginterferon-α, and ribavirin. In another landmark event, the initial approval of sofosbuvir included HCV/HIV-1 coinfected patients. Simeprevir and sofosbuvir also provide a window to the future with sustained virologic response (SVR) rates of >90% for genotype 1 when these agents are combined. Interferon-free regimens for genotype 1 patients have anticipated approvals in late 2014 or early 2015. Clinicians and patients will have the opportunity to discuss and select from current treatment options or await upcoming regimens. These potent new agents provide the tools to cure HCV for many patients.

1 March 2009 in Psychosomatics
Verified
Journal Article
Closed access
DBDonald E. Bailey
Donald E. Bailey
LLLawrence Landerman
Lawrence Landerman
JBJulie Barroso
Julie Barroso
PBPatricia Bixby
Patricia Bixby
MMMerle H. Mishel
Merle H. Mishel
ECElizabeth Clipp
Elizabeth Clipp